Pharmaceuticals
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational ne...
2022-08-03 20:00
2655
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...
2022-08-03 19:38
2667
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients
-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...
2022-08-03 16:50
3817
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:02179.HK) is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine,...
2022-08-03 13:09
5055
Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. * ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...
2022-08-03 08:30
3080
Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China
- Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose - Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved HbA1c ≤6.5% at the end of the 20-week treatment - XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly reported adve...
2022-08-03 08:00
3752
Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China
HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for clinical tr...
2022-08-03 08:00
4061
Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies
SHANGHAI, Aug. 3, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...
2022-08-03 08:00
3469
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...
2022-08-02 22:49
4947
GenKOre develops hypercompact base editing system
DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage:
www.genkore.com
2022-08-02 22:44
2835
Metabolon Awarded ISO 9001:2015 Recertification
ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...
2022-08-02 20:57
2241
CARsgen Appoints Dr. Hua Jiang as Executive Director
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...
2022-08-02 20:50
3153
Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...
2022-08-02 20:39
2426
Chime Biologics Received Commercial Manufacturing License Indicating the Kick-off into the Era of Commercial Production
* GMP commercial manufacturing license authorized by the National Drug Regulatory Authority, demonstrating Chime Biologics' capabilities in large scale commercial production * Only 18 months to help LEPU Biopharma to obtain the approval of Puyouheng ™ ina new drug application demonstrating "...
2022-08-02 20:15
2095
Dr Ivan Puah Recommends Fat Grafting As A Solution Following Post-surgery Scars or Disfigurement
Fat grafting is highly recommended as part of the corrective surgery method to correct facial or body disfigurement from liposuction, laparoscopy or surgeries that cause dents and irregular contours. SINGAPORE, Aug. 2, 2022 /PRNewswire/ -- Dr Ivan Puah, Medical Director at Amaris B. Clinic,...
2022-08-02 16:41
3200
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency
Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands, Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Na...
2022-08-02 13:00
3986
NEXTSTELLIS® oral contraceptive has been nominated for the 2022 prix galien usa award for best pharmaceutical agent
ADELAIDE, Australia, Aug. 2, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix GalienUSA Award for Best Pharmaceutical A...
2022-08-02 13:00
2744
GenKOre develops hypercompact adenine base editors (ABEs)
DAEJEON, South Korea, Aug. 2, 2022 /PRNewswire/ -- GenKOre, a biotech start-up
in Korea, succeeded in the development of ABEs based on its own hypercompact
gene-editing technology and had the relevant study published on Nature Chemical
Biology onAugust 2, 2022.
2022-08-02 09:07
3637
AVer Introduces Revolutionary Detachable Medical Grade Cameras
NEW TAIPEI CITY, Taiwan, Aug. 2, 2022 /PRNewswire/ -- AVer Information Inc., the award-winning provider of video collaboration and education technology solutions, is excited to introduce its Connected Health Solutions, which was created from AVer's dedication in understanding and contributing to ...
2022-08-02 09:00
3498
Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations
CAMBRIDGE, Mass. and SUZHOU, China, Aug. 2, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced the appointment ofAngela (Hui) Yan as President of China and Asi...
2022-08-02 07:00
4798
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 283 media titles]
2026-10-19 13:18
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 280 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
31105
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
26754
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
24661
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
24499